Navigation Links
Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
Date:11/27/2007

lopment activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as amended, and most current Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2007 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , August 20, 2014 ... of Glenmark Pharmaceuticals Limited India (GPL), announces the ... a novel clinical development candidate, GBR 1302, a ... developed by the Glenmark Biologics Research Centre located ... GBR 1302 is based on Glenmark,s innovative BEAT ...
(Date:8/19/2014)... Tenn. , Aug. 19, 2014   ... provide its patient experience technology to ... Under the five-year agreement, CarePoint Health will deploy ... Bayonne Medical Center, Christ Hospital and Hoboken University ... offers a range of software solutions to help ...
(Date:8/19/2014)... 19, 2014 Talyst, a market leader in ... the 2014 NPPA Summer Conference in Las ... its 340B software products and services.   ... supplying over 400 customers with a variety of software ... including its latest solution, AutoSplit® Contract Pharmacy and 340B ...
Breaking Medicine Technology:Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2Talyst Exhibits at the NPPA Summer Conference 2
... Development of New Vaccines to Prevent Tuberculosis , ... ROCKVILLE, Md. , July 1 ... E. Connolly has been named President and Chief Executive Officer.  He ... Executive Vice President and General Manager of Wyeth Vaccines.  He will take ...
... , July 1 The refinements in ... the fifth generation Leksell Gamma Knife® Perfexion™ are radically ... and other brain disorders. With Perfexion, physicians are applying ... treating more non-malignant targets located in critical areas and ...
Cached Medicine Technology:Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO 2Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO 3Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO 4Physicians See New Benefits, Treatment Opportunities for Brain Cancer with Elekta's Leksell Gamma Knife Perfexion 2Physicians See New Benefits, Treatment Opportunities for Brain Cancer with Elekta's Leksell Gamma Knife Perfexion 3Physicians See New Benefits, Treatment Opportunities for Brain Cancer with Elekta's Leksell Gamma Knife Perfexion 4Physicians See New Benefits, Treatment Opportunities for Brain Cancer with Elekta's Leksell Gamma Knife Perfexion 5
(Date:8/20/2014)... researchers have discovered that the immune system is defective in ... reason why sufferers have ongoing issues with pain. , The ... could also help to explain why some painkillers may ... (IBS) affects up to 10% of the community. There ... unexplained gut pain, which often has the greatest impact on ...
(Date:8/20/2014)... Barbara Bronson Gray ... -- Although it,s extremely rare, colds, flu and other ... elevated risk for stroke in children, a new study suggests. ... a stroke in the United States, said Dr. Heather Fullerton, ... and pediatrics at the University of California, San Francisco Benioff ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The Board ... Perkins Eastman is pleased to announce the ... services in China and the surrounding region. ... Richard Sprow AIA has relocated to the ... career in healthcare planning and design and to better ...
(Date:8/20/2014)... August 20, 2014 With 3943.8% growth, Connexion ... of the nation’s fastest growing companies. The Inc. 500 ranks ... care sector. Connexion Point is the #1 fastest growing company ... Medicare and Medicaid, and its clients include four of the ... employs 1,000 people and has offices and contact centers in ...
(Date:8/20/2014)... that the amygdala stimulates stress responses in adults, ... University have found that the amygdala has an ... development of nonhuman primates. , The results are ... . , The amygdala is a region of ... to threatening situations and learning about threats. Alterations ...
Breaking Medicine News(10 mins):Health News:Pain treatments less effective for those with irritable bowel 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3
... who feel powerful are more likely to believe they ... according to new study in the Journal of ... anthropomorphism, or the tendency to attribute humanlike characteristics, intentions, ... important downstream consequences of anthropomorphism that go beyond simple ...
... , WEDNESDAY, Dec. 22 (HealthDay News) -- Women who ... to give birth to a single healthy baby following the ... to have two embryos implanted at the same time, an ... from an analysis of data involving nearly 1,400 women who ...
... News) -- How people fare when oral cancer recurs depends ... has found. The research included 77 people in Australia ... in the thin, flat cells that line the lips and ... However, the cancer came back, and they all subsequently had ...
... --- Busy doctors can miss important details about a ... Northwestern Medicine researchers have created a whip-smart assistant for ... that alerts doctors during an exam when a patient,s ... software program significantly improved primary care physicians, performance and ...
... are offered fewer and less effective choices ... deaths, according to a new UCSF study. The ... prostate cancer often are under-treated through hormone therapy or ... such as surgery and radiation therapies. Instead, say the ...
... HealthDay Reporter , TUESDAY, Dec. 21 (HealthDay News) -- The ... to play in helping people who have trouble connecting to ... a small group of healthy people, investigators found that the ... of friendliness, playfulness and love, and induced a lowering of ...
Cached Medicine News:Health News:Why do risks with human characteristics make powerful consumers feel lucky? 2Health News:Single Embryo Beat Double Embryo Transfer in IVF Study 2Health News:Single Embryo Beat Double Embryo Transfer in IVF Study 3Health News:Recurrence of Oral Cancer Found to Signal Poor Outcome 2Health News:Smarter systems help busy doctors remember 2Health News:Smarter systems help busy doctors remember 3Health News:Age plays too big a role in prostate cancer treatment decisions 2Health News:Age plays too big a role in prostate cancer treatment decisions 3Health News:Does 'Club Drug' Ecstasy Have Therapeutic Value? 2Health News:Does 'Club Drug' Ecstasy Have Therapeutic Value? 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: